Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab.

Guillaume Nugue 1 Marie Bidart 2 Marie Arlotto 1 Mireille Mousseau 3 François Berger 2 Laurent Pelletier 2, *
* Auteur correspondant
1 Inserm U836, équipe 7, Nanomédecine et cerveau
GIN - Grenoble Institut des Neurosciences
2 INSERM U836, équipe 7, Nanomédecine et cerveau
GIN - Grenoble Institut des Neurosciences, Service d'oncologie médicale
Abstract : Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied with monoclonal antibodies. As a consequence, the efficacy or side effects associated with this type of treatment often appear to be sporadic. Bevacizumab is a therapeutic monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF). It is used to limit tumor vascularization. No prognosis or response biomarker is associated with this antibody, we therefore assessed whether the administration protocol could be a possible cause of heterogeneous responses (or variable efficacy). To do this, we developed a bevacizumab assay with a broad sensitivity range to measure blood bevacizumab concentrations. We then analyzed bevacizumab concentrations in 17 patients throughout the first quarter of treatment. In line with previously published data, average blood concentrations were 88+/-27 mg/L following the first dose administered, and 213+/-105 mg/L after the last (6(th)) dose administered. However, the individual values were scattered, with a mean 4-fold difference between the lowest and the highest concentration for each dose administered. We demonstrated that the bevacizumab administration schedule results in a high inter-individual variability in terms of blood concentrations. Comparison of assay data with clinical data indicates that blood concentrations above the median are associated with side effects, whereas values below the median favor inefficacy. In conclusion, bevacizumab-based therapy could benefit from a personalized administration schedule including follow-up and adjustment of circulating bevacizumab concentrations.
Type de document :
Article dans une revue
PLoS ONE, Public Library of Science, 2013, 8 (8), pp.e72021. 〈10.1371/journal.pone.0072021〉
Liste complète des métadonnées

Littérature citée [17 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-00854640
Contributeur : Jean-Paul Issartel <>
Soumis le : mardi 27 août 2013 - 17:04:06
Dernière modification le : jeudi 1 février 2018 - 01:11:46
Document(s) archivé(s) le : jeudi 6 avril 2017 - 09:33:04

Fichier

Nugue-2013_Monitoring_AO.pdf
Fichiers éditeurs autorisés sur une archive ouverte

Identifiants

Collections

UGA | U836

Citation

Guillaume Nugue, Marie Bidart, Marie Arlotto, Mireille Mousseau, François Berger, et al.. Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab.. PLoS ONE, Public Library of Science, 2013, 8 (8), pp.e72021. 〈10.1371/journal.pone.0072021〉. 〈inserm-00854640〉

Partager

Métriques

Consultations de la notice

442

Téléchargements de fichiers

152